Evidence map›Paper›PMID 24578608›Full record

ArticleInternational journal of medical sciences2014

Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma.

Tetsuya Minegaki, Akiko Kuwahara, Motohiro Yamamori, Tsutomu Nakamura, Tatsuya Okuno, Ikuya Miki, Hideaki Omatsu, Takao Tamura, Midori Hirai, Takeshi Azuma and 2 more

Open access · goldAbstract read
In one paragraph

Article in International journal of medical sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. ROS-modulated therapeutic approaches in cancer treatment.Journal of cancer research and clinical oncology · 2017
    Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 1 country.

Tetsuya Minegaki1. Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Akiko Kuwahara2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. ; 3. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
Motohiro Yamamori2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. ; 3. School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, Nishinomiya 663-8179, Japan.
Tsutomu Nakamura2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Tatsuya Okuno2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Ikuya Miki2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Hideaki Omatsu2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Takao Tamura2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. ; 4. Department of Medical Oncology, Nara Hospital, Kinki University Faculty of Medicine, Nara 630-0293, Japan.
Midori Hirai2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Takeshi Azuma2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Toshiyuki Sakaeda2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. ; 5. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan.
Kohshi Nishiguchi1. Faculty of Pharmaceutical Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan. ; 2. Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.
Kobe University · JPMukogawa Women's University · JPKobe Pharmaceutical University · JPKobe University Hospital · JPKyoto Pharmaceutical University · JPKyoto University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveDefinitive chemoradiotherapy (CRT) with 5-fluorouracil (5-FU) and cisplatin (CDDP) is one of the standard therapies for esophageal squamous cell carcinoma (ESCC); however, inter-individual variations in clinical outcomes have yet to be investigated. In the present study, single nucleotide polymorphisms (SNPs) in SLC23A2 gene were retrospectively evaluated in 49 Japanese patients with ESCC who were treated with a definitive 5-FU/CDDP-based CRT, and the predictive values for the clinical response, severe acute toxicities, and long-term survival were assessed.

methodsA course consisted of the continuous infusion of 5-FU at 400 mg/m(2)/day for days 1-5 and 8-12, the infusion of CDDP at 40 mg/m(2)/day on days 1 and 8, and radiation at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19, with a second course being repeated after a 2-week interval. The SLC23A2 SNPs rs2681116, rs13037458, rs1715364, rs4987219, and rs1110277 were evaluated.

resultsThe rs2681116 and rs13037458 had a tendency to predict the clinical response (p=0.144 and 0.085, respectively) and long-term survival (p=0.142 and 0.056, respectively). The rs4987219 and rs1110277 correlated with severe acute leukopenia (p=0.025) and stomatitis (p=0.019), respectively.

conclusionsFurther investigations with a larger number of patients or an in vitro study are needed to confirm the predictive values of genetic polymorphisms in SLC23A2.

Indexed as

AgedAsian PeopleCarcinoma, Squamous CellCisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleFluorouracilGenotypeHumansMaleMiddle AgedPolymorphism, Single NucleotideRetrospective StudiesSodium-Coupled Vitamin C TransportersTreatment OutcomeCisplatinFluorouracilSLC23A2 protein, humanSodium-Coupled Vitamin C Transportersbiomarkerchemoradiotherapyesophageal squamous cell carcinomapolymorphism.SLC23A2

Identifiers

PMID24578608
PMCPMC3936025
OpenAlexW2121364309

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.